nmol l tumor necrosis factor (R&D Systems)
Structured Review
Nmol L Tumor Necrosis Factor, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1779 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+protein/Recombinant+Human+TNF-alpha+Protein/pmc13054578-103-43-49
Average 97 stars, based on 1779 article reviews
Images
Related Articles
SDS Page:Article Title: SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2. Article Snippet: .. Protein-containing samples in SDS-PAGE sample buffer were subjected to electrophoresis and immunoblotting using the following primary antibodies: SFN (1:1000, in-house), Shp2 (1:1000, Abcam #32083) for Article Title: SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2 Article Snippet: .. Protein-containing samples in SDS-PAGE sample buffer were subjected to electrophoresis and immunoblotting using the following primary antibodies: SFN (1:1000, in-house), Shp2 (1:1000, Abcam #32083) for Electrophoresis:Article Title: SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2. Article Snippet: .. Protein-containing samples in SDS-PAGE sample buffer were subjected to electrophoresis and immunoblotting using the following primary antibodies: SFN (1:1000, in-house), Shp2 (1:1000, Abcam #32083) for Article Title: SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2 Article Snippet: .. Protein-containing samples in SDS-PAGE sample buffer were subjected to electrophoresis and immunoblotting using the following primary antibodies: SFN (1:1000, in-house), Shp2 (1:1000, Abcam #32083) for Western Blot:Article Title: SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2. Article Snippet: .. Protein-containing samples in SDS-PAGE sample buffer were subjected to electrophoresis and immunoblotting using the following primary antibodies: SFN (1:1000, in-house), Shp2 (1:1000, Abcam #32083) for Article Title: SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2 Article Snippet: .. Protein-containing samples in SDS-PAGE sample buffer were subjected to electrophoresis and immunoblotting using the following primary antibodies: SFN (1:1000, in-house), Shp2 (1:1000, Abcam #32083) for Recombinant:Article Title: SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2. Article Snippet: .. Protein-containing samples in SDS-PAGE sample buffer were subjected to electrophoresis and immunoblotting using the following primary antibodies: SFN (1:1000, in-house), Shp2 (1:1000, Abcam #32083) for Article Title: SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2 Article Snippet: .. Protein-containing samples in SDS-PAGE sample buffer were subjected to electrophoresis and immunoblotting using the following primary antibodies: SFN (1:1000, in-house), Shp2 (1:1000, Abcam #32083) for Article Title: The co-delivery of Programmed Death 1 ligands enhances and prolongs rAAV-mediated gene expression in pre-immunized mice Article Snippet: NP-40 lysates of transfected 293T cells were precleared with HisPur Ni-NTA Magnetic Beads (Thermo Scientific). .. Lysates were collected, supplied with 2.5 μg of PD1-His (cat# 8986-PD-100, R&D Systems) Article Title: Substituted 1,2,4-triazoles as TYK2 inhibitors Article Snippet: .. A 10-point dilution series of test compound (top dose 10 uM, 1:5 dilution) was added to the well using the liquid dispenser (Tecan D300e) and incubated for 1 hour at 37 C. Then human IL-12 Article Title: Identification of a SNAI1 enhancer RNA that drives cancer cell plasticity. Article Snippet: Anti-BRD4 antibody (Cell Signaling Technology; 13440), anti-YTHDC1 antibody (Cell Signaling Technology; 77422s), or normal rabbit IgG was incubated with MDA-MB-231 cell lysates for 16 h at 4 °C. .. For in vitro RIP, 10 pmol of in vitro-transcribed SNAI1e was incubated with 2 μg recombinant FLAG-SMURF2 protein (Sigma‒Aldrich; SRP0228) or FLAG-BRD4 BD1/2 Immunoprecipitation:Article Title: SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2. Article Snippet: .. Protein-containing samples in SDS-PAGE sample buffer were subjected to electrophoresis and immunoblotting using the following primary antibodies: SFN (1:1000, in-house), Shp2 (1:1000, Abcam #32083) for Article Title: SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2 Article Snippet: .. Protein-containing samples in SDS-PAGE sample buffer were subjected to electrophoresis and immunoblotting using the following primary antibodies: SFN (1:1000, in-house), Shp2 (1:1000, Abcam #32083) for other:Article Title: Bispecific antibody Article Snippet: The clones CD19-1(Bi) to CD19-5(Bi) or control antibody were added thereto, and IgM contained in the culture supernatant after activation treatment was quantified by ELISA (ThermoFisher, Serial No. BMS 2098). Article Title: Identification of a SNAI1 enhancer RNA that drives cancer cell plasticity. Article Snippet: MDA-MB-231 cells stably expressing Cas9 (Addgene; 98290) were transduced with gRNA expression constructs by lentivirus infection. Article Title: Bispecific antibody Article Snippet: Note here that for immobilization of the recombinant proteins, Series S Sensor Chip CM5 Sensor Chip (GE Health Care, serial number 29-1049-88) was used. Incubation:Article Title: The co-delivery of Programmed Death 1 ligands enhances and prolongs rAAV-mediated gene expression in pre-immunized mice Article Snippet: NP-40 lysates of transfected 293T cells were precleared with HisPur Ni-NTA Magnetic Beads (Thermo Scientific). .. Lysates were collected, supplied with 2.5 μg of PD1-His (cat# 8986-PD-100, R&D Systems) Article Title: Substituted 1,2,4-triazoles as TYK2 inhibitors Article Snippet: .. A 10-point dilution series of test compound (top dose 10 uM, 1:5 dilution) was added to the well using the liquid dispenser (Tecan D300e) and incubated for 1 hour at 37 C. Then human IL-12 Article Title: Identification of a SNAI1 enhancer RNA that drives cancer cell plasticity. Article Snippet: Anti-BRD4 antibody (Cell Signaling Technology; 13440), anti-YTHDC1 antibody (Cell Signaling Technology; 77422s), or normal rabbit IgG was incubated with MDA-MB-231 cell lysates for 16 h at 4 °C. .. For in vitro RIP, 10 pmol of in vitro-transcribed SNAI1e was incubated with 2 μg recombinant FLAG-SMURF2 protein (Sigma‒Aldrich; SRP0228) or FLAG-BRD4 BD1/2 Concentration Assay:Article Title: Substituted 1,2,4-triazoles as TYK2 inhibitors Article Snippet: .. A 10-point dilution series of test compound (top dose 10 uM, 1:5 dilution) was added to the well using the liquid dispenser (Tecan D300e) and incubated for 1 hour at 37 C. Then human IL-12 In Vitro:Article Title: Identification of a SNAI1 enhancer RNA that drives cancer cell plasticity. Article Snippet: Anti-BRD4 antibody (Cell Signaling Technology; 13440), anti-YTHDC1 antibody (Cell Signaling Technology; 77422s), or normal rabbit IgG was incubated with MDA-MB-231 cell lysates for 16 h at 4 °C. .. For in vitro RIP, 10 pmol of in vitro-transcribed SNAI1e was incubated with 2 μg recombinant FLAG-SMURF2 protein (Sigma‒Aldrich; SRP0228) or FLAG-BRD4 BD1/2 |





![( A ) Schematic protocol for differentiation of PBMC-derived monocytes from secretor-negative or -positive donor with <t>M-CSF</t> (50 ng/ml; M0 <t>macrophage),</t> <t>GM-CSF</t> (50 ng/ml; M1 macrophage), or M-CSF (50 ng/mL) plus dexamethasone (1 μM; M2 macrophage) for 7 days, followed by GII.4 norovirus inoculation. Created in BioRender. Y. Matsushima (2026; https://BioRender.com/go5bv1s ). ( B ) Heatmap of differential gene expression among M0, M1, and M2 macrophages at 3 hpi by bulk RNA-seq (three biological replicates/group). ( C ) Extracellular norovirus RNA levels in M0, M1, and M2 macrophages from a secretor-negative donor following GII.4[P16] inoculation (9.34 × 10 4 copies; three biological replicates per group). ( D ) Extracellular viral RNA levels at 3 hpi and 5 dpi in M0, M1, and M2 macrophages from a secretor-positive donor (four experiments). ( E ) Identification of norovirus-infected cells in M2 macrophages from a secretor-positive donor at 1 dpi by immunofluorescence assay. dsRNA, green; VP1, red; DAPI, blue. Scale bars, 10 μm. ( F ) Extracellular viral RNA levels following untreated or UV-inactivated GII.4[P16] inoculation onto M2 macrophages from a secretor-positive donor (duplicate/triplicate experiments). ( G ) Restricted replication of GII.4[P16] (9.34 × 10 4 copies) or GII.3[P21] (3.09 × 10 5 copies) in M2 macrophages (Secretor-positive donor) with or without GCDCA (500 μM; duplicate experiments). ( H ) Extracellular viral RNA levels in M2 macrophages from Pts. 1 and 2 following GII.4[P31] inoculation (3.92 × 10 5 copies). ( I ) Detection of norovirus-infected cells in M2 macrophages (Pt. 1) at 1 dpi by immunofluorescence assay. dsRNA, green; VP1, red. Scale bars, 5 μm. Viral RNA was quantified by RT-qPCR. Statistics: two-way ANOVA with Tukey’s multiple-comparisons test [(C), (D), (F), and (G)] and two-way ANOVA with uncorrected Fisher’s LSD (H). * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_4023/pmc13754023/pmc13754023__sciadv.aej2676-f8.jpg)